Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101A. A. Miller, Mark J. Ratain, Donna Hollis et al.|Journal of Clinical Oncology|2006Cited by 2